However, unlike other newer antidiabetic drugs, DPP-4 inhibitors do not appear to exert meaningful effects on macrovascular or microvascular risk, at least when administered for periods of 34 years
Xu L, Chen Y, Jin Q, Gao T, Deng C, Wang R, et al
The glutathione UK industry is governed by strict standards to help ensure patients receive high-quality care
Stephanie Weiss, M.D., Ph.D., assistant director for the Clinical Research, Medication Development Program at NIDA, shared data from the first published clinical trial of GLP-1 RAs in alcohol use disorder: in patients with obesity with a BMI over 30, exenatide reduced heavy drinking days by 23.6% and lowered total alcohol intake